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Althoughthemajorityofsmoothmuscleneoplasmsfoundintheuterusarebenign,uterineleiomyosarcoma
(LMS) is extremely malignant, with high rates of recurrence and metastasis. We earlier reported that mice
with a homozygous deficiency for LMP2, an interferon (IFN)-c-inducible factor, spontaneously develop
uterine LMS. The IFN-c pathway is important for control of tumor growth and invasion and has been
implicated in several cancers. In this study, experiments with human and mouse uterine tissues revealed a
defective LMP2 expression in human uterine LMS that was traced to the IFN-c pathway and the specific
effect of JAK-1 somatic mutations on the LMP2 transcriptional activation. Furthermore, analysis of a
human uterine LMS cell line clarified the biological significance of LMP2 in malignant myometrium
transformation and cell cycle, thus implicating LMP2 as an anti-tumorigenic candidate. This role of LMP2
as a tumor suppressor may lead to new therapeutic targets in human uterine LMS.
S
mooth muscle tumors (SMTs) are commonly divided into benign leiomyoma (LMA) and malignant
leiomyosarcoma (LMS) based on cytological atypia, mitotic activity, and other criteria. Uterine LMS is a
very rare gynecologic malignancy in the female genital tract, having an estimated annual incidence of 0.64
per 100,000 women
1. LMS accounts for approximately one-third of uterine sarcomas, of which only 53% are
confined to the uterus
2–5. Gynecological cancers, which include breast cancer and endometrial carcinomas, are
strongly promoted by female hormones, but the rate of hormone receptor expression is reported to be signifi-
cantly lower in human uterine LMS than in normal myometrium. These low receptor levels were found to
correlate neither with the promotion of initial disease development, nor with the overall survival of patients with
uterine LMS.
AlthoughuterineLMSissensitivetocertaintypesofchemotherapywithgemcitabineordocetaxel,itisresistant
to hormone therapy and radiotherapy, and thus surgical intervention is virtually the only means of treatment at
this time
6–8. It should be noted that when adjusting for stage and mitotic count, LMS has a significantly worse
prognosis than carcinosarcoma
11; the 5-year survival rate for patients with uterine LMS is 15%–25%. The
development of efficient adjuvant treatments is expected to improve the outcome of this disease through the
useofpromisingnewmoleculartargetingtherapies
4,5,9,10.Thedeterminationofthemalignantpotentialofsmooth
muscle neoplasms also represents a significant diagnostic conundrum with important therapeutic ramifications.
However, the genetic changes underlying the neoplastic transformation of uterine smooth muscle cells have not
been fully characterized. Moreover, diagnostic biomarkers that are able to distinguish between LMS and LMA
have yet to be established.
The ubiquitin-proteasome degradation pathway is essential for many cellular processes, including cell
cycle, regulation of gene expression, and response to oxidative stress. Therefore, individual expression of
the low molecular weight protein (LMP)2, LMP7, and LMP10 (MECL-1) subunits are believed to contribute
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revealed a unique role for LMP7 in controlling pathogenic
immune responses and provided a therapeutic rationale for tar-
geting LMP7 in autoimmune disorders, especially rheumatoid
arthritis
12. It is also noteworthy that mice with a targeted disrup-
tion of LMP2, which is an interferon (IFN)-c-inducible protea-
some subunit, exhibited defects in tissue- and substrate-dependent
proteasomal function, and that female LMP2-deficient mice spon-
taneously developed uterine LMS with a disease prevalence of 37%
by 12 months of age
13,14 (see Supplementary Fig. S1 online).
Defective LMP2 expression is therefore likely to be one of the risk
factors in the development of human uterine LMS as it is in
LMP2-deficient mice
14,15. The importance of the IFN-c pathway
in the transcriptional regulation of the LMP2 promoter has been
established in another study, where defective LMP2 expression
was attributable to a G871E mutation in the ATP-binding region
of JAK1 in a SKN cell line established from a patient with uterine
LMS
15.
In the present study, we investigated whether LMP2 expression
wasmarkedlydown-regulatedinhumanuterineLMStissuesincom-
parison with both LMA and normal myometrium. Biological and
histological findings showed that defective LMP2 expression con-
tributed to abnormal cell proliferation, which directly correlated to
tumor progression. Disruption of LMP2 expression stemmed from
defects in the IFN-c signaling pathway, specifically from somatic
mutations in JAK1. Furthermore, LMP2 expression appeared to be
responsible for the suppression of specific transformed phenotypes
ofhumanuterineLMScellsinananti-oncogenicmanner.Continued
improvement of our knowledge of the molecular biology of uterine
LMS may ultimately lead to novel diagnoses and therapies and
improved outcome.
Results
Defective LMP2 expression in human uterine LMS. The effects of
IFN-c on LMP2 expression were examined using five cell lines
15.
LMP2 expression was not markedly induced by IFN-c treatment
in human uterine LMS cells, although cervical epithelial adeno-
carcinoma cell lines and normal human myometrium showed
strong expression of LMP2 following IFN-c treatment
15. Further-
more, immunohistochemistry (IHC) revealed a pronounced loss in
the ability to induce LMP2 expression in human uterine LMS tissue
incomparisonwithnormalmyometriumlocatedinthesamesection
(Fig. 1a,c and see Supplementary Fig. S2 online). Of the 54 patients
with uterine LMS that we examined, 46 were negative for LMP2
expression, 4 were focally positive, and 2 were partially positive
(Fig. 1c). Two LMS patients were analyzed for LMP2 expression
(Fig. 1c). LMP2 levels were also evaluated in skeletal muscle and
rectal metastases from individual uterine LMS patients (see
Supplementary Fig. S3 online), where surgical samples showed the
presence of a mass measuring 3 cm in maximum diameter in the
lumbar quadrate muscle without a fibrous capsule. All lymph nodes
were negative for LMS metastases, and IHC analyses showed
positivity for MIB1(Ki-67) and negativity for LMP2. The defective
LMP2expressiondetectedinprimaryuterineLMSwasalsoobserved
in the metastatic LMS of the skeletal muscle and rectum, indicating
that the metastatic lesions conserved this biological characteristic of
primary uterine LMS (see Supplementary Fig. S3 online). In both
Western blotting and RT-PCR experiments, LMP2 was expressed in
normalmyometrium butnotinhuman uterineLMS(Fig.1b),which
was strongly supportive of the IHC findings. Although our research
group has previously demonstrated that the abnormal expression of
theovariansteroidreceptorsTP53andKi-67andmutationsofTP53
were frequently associated with uterine LMS, defective LMP2
expression appeared to be more characteristic of uterine LMS (see
Supplementary Table S1 online).
Key role of the IFN-c-pathway for LMP2 expression in myo-
metrium tissue. While it has been established that IFN-c
markedly enhances LMP2 production through JAK-STAT
signaling, the NF-kB signaling pathway also reportedly induces
LMP2 gene expression in an independent manner; inhibition of
NF-kB signaling resulted in a decrease in LMP2 expression in
human carcinoma cell lines and human lymphocytes
16–18 (Fig. 2a
and see Supplementary Fig. S4 online). However, the essential
signaling pathway for LMP2 expression in myometrium is not yet
clearlyunderstood.WeperformedexperimentswithIFN-c-deficient
mice and TNF-a-deficient mice to elucidate the molecular mecha-
nism of Lmp2 gene expression in myometrium. Although LMP2
expression was detected in several tissues (heart, ventriculus,
esophagus, liver) obtained from IFN-c- and TNF-a-deficient mice
atasimilar basal expression level asage-matched wild type mice (see
Supplementary Fig. S5 online), the myometrium of IFN-c-deficient
mice had non-identical LMP2 expression in comparison with TNF-
a-deficient mice and wild-type mice (Fig. 2b). IHC experiments
revealed that IFN-c was especially required for LMP2 expression
in myometrium, and Western blotting and RT-PCR showed that
IFN-c-deficient mice had markedly decreased levels of LMP2
(Fig. 2c). Examination of mice lacking RelA or NF-kBp65 could
not be performed due to embryonic lethality
19.
To demonstrate whether LMP2 expression was positively regu-
lated by the IFN-c pathway in human and mouse myometria, chro-
matin immunoprecipitation (ChIP) was carried out on uterine
organs obtained from patients and mice. IRF-1, an IFN-c-inducible
factor, induced LMP2 gene expression as part of an initiation com-
plex with the LMP2 regulatory region of the genome (Fig. 2d). We
next examined whether IRF-1wasnecessary forLMP2gene express-
ion in human and mouse myometria by ChIP assays on uterine
organs from patients and IFN-c- and TNF-a-deficient and age-
matched wild type mice. RelA did not clearly bind to the Lmp2
regulatory region of the genome in any mouse group (Fig. 2e).
Conversely, IRF-1 bound to the Lmp2 regulatory region in TNF-a-
deficient mice andwild-type mice, butadeficiency inIFN-cresulted
in undetectable IRF-1 occupancy in the Lmp2 regulatory region
(Fig. 2e). RelA was not detected in the initiation complex with the
LMP2 regulatory region in tumor tissue sections, LMA, LMS, or
normal myometrium tissue sections derived from patient uterine
organs (Fig. 2f). Although IRF-1 bound to the LMP2 regulatory
region in normal myometrium and LMA patient tissue sections,
LMS tissue sections demonstrated weak IRF-1 occupancy of the
LMP2 regulatory region (Fig. 2f and see Supplementary Fig. S6
online). The ubiquitous nuclear factor SP1 directly binds to a GC
box and positively regulates basal transcription of LMP2, which is
TATA-less gene. SP1 was detected in the initiation complex of the
regulatoryregionoftheLMP2geneinalltestedtumortissuesections
(see Supplementary Fig. S6 online). Therefore, IFN-c signaling was
requiredtoallowIRF-1bindingtotheLMP2regulatoryregionofthe
genome in human uterine organs. Taken together, these findings
demonstrated that the IFN-c signaling pathway likely played a key
role in LMP2 expression in myometrium.
Mutations in IFN-c signaling molecules in human LMS. Since the
IFN-c pathway was revealed to play a key role in basal LMP2
expression in normal human myometrium (Fig. 2), we next
focused on whether the defect in LMP2 expression in uterine LMS
wasattributable to mutations or deletions in IFN-c signaling factors.
FollowingIFN-cbindingtothetype IIIFNreceptor, Janus-activated
kinase (JAK) 1 and JAK2 are activated and phosphorylate signal
transducer and activator of transcription (STAT) 1 on the tyrosine
residue at position 701 (Tyr701) and the serine residue at position
727 (Ser727)
20,21 (see Supplementary Fig. S4 online). Tyrosine-
phosphorylated STAT1 forms homodimers that translocate to the
nucleus and bind to IFN-c-activated site (GAS) elements in the
www.nature.com/scientificreports
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20,21 (see Supplementary Fig. S4
online). The phosphorylation of Ser727 is required for full trans-
criptional activation of LMP2
20,21.
SequenceanalysisdemonstratedthatthelossofIFN-cresponsive-
nessinahumanuterineLMScelllineswasattributabletoinadequate
JAK1 kinase activity due to a G781E mutation in the ATP-binding
region
15.Genetic alterationsintyrosine kinases havepreviouslybeen
firmly implicated in tumorigenesis, but only a few serine/threonine
kinases are known to be mutated in human cancers
21–27. The exam-
ination of 19LMS tissue sections and patient-matched normal tissue
controls was performed to identify somatic (tumor-specific) muta-
tions in the catalytic domains of the IFN-c-signaling factors JAK1,
JAK2,STAT1,andLMP2enhancer/promoterregion.Asthecatalytic
domainsofthesegeneswerethemostlikelytoharbormutationsthat
activate the gene product, we focused on exon stretches con-
taining kinase domains, transcriptional activation domains, and the
enhancer/promoter regionfortheLMP2gene.The cDNAfragments
of these molecules were amplified and directly sequenced. Com-
parison of cDNA sequences obtained from LMS tissue sections, nor-
mal tissue sections, the catalytic domains of JAK1 (JAK1 Accession,
M64174.1; JAK2 Accession, AF005216.1; STAT1 Accession,
NM_007315), and the LMP2 enhancer/promoter region (NCBI
Reference, homo sapiens chromosome 6 NT_007592.15) demon-
strated the presence of a total of eight point mutations that were
confirmed by re-sequencing in both the sense and antisense direc-
tions. Overall, nearly 36.8% (7/19) of uterine LMS tissues had so-
matic mutations in the ATP-binding region or kinase active site of
JAK1(seeSupplementaryFig.S7online).Furthermore,31.6%(6/19)
of uterine LMS tissues had somatic mutations in essential sites of the
LMP2 enhancer/promoter region required for LMP2 transcriptional
activation (see Supplementary Table S2–S3 online). No soma-
tic mutations at Tyr701 or Ser727, which are needed for STAT1
Figure 1 | Defect in LMP2 expression in human uterine leiomyosarcoma (LMS) tissue. (a) Immunohistochemistry (IHC) of LMP2 in normal
myometrium (patient #17
a), uterine leiomyoma (LMA, patient UL1
b) and uterine LMS (patient #17
a) tissues located in the same tissue. For all samples,
5 mm sections of tissue were stained with anti-LMP2 antibody and revealed by peroxidase-conjugated anti-rabbit IgG antibody. (magnification x100)
a,bDetailsofpatientswithLMAorLMSareshowninTable.S1andFig.S6.(b)Cytosolicextractswerepreparedfromnormalhumanmyometrium(patient
#17
a), uterine leiomyoma (LMA, patient UL1
b), and uterine LMS (patient #17
a) tissues. Extracts of 50 mg were resolved by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The levels of LMP2 and b-actin were examined by immunoblot analysis with appropriate antibodies.
Examinations of mRNA expression for LMP2, b2-m, and b-actin in normal myometrium (Myo.), uterine LMA, and uterine LMS were performed by
reverse transcription-polymerase chain reaction (RT-PCR) with the appropriate primers indicated in the Materials and Methods section. The DNA
products amplified by RT-PCR were loaded onto agarose gels.
aDetails are shown in Table S1 and Table S2,
bdetails are shown in Fig. S6. (c) IHC
experiments individually performed at several medical facilities revealed a marked loss in the ability to induce LMP2 expression in human uterine LMS
tissues compared to that in normal myometrium located in the same tissue section, as well as to that in LMA tissues. Normal total: 55 cases, LMA total:
48 cases, Bizarre Leiomyoma total: 3 cases, LMS total: 54 cases. The experiments were performed three times with similar results.
www.nature.com/scientificreports
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(5/19) of uterine LMS tissues unexpectedly had mutations in the
STAT1 intermolecular region, an area not yet reported to be of
importance for transcriptional activation or other biological func-
tions (see Supplementary Table S2–S3 online). No somatic muta-
tions in the catalytic domains of JAK2 were detected in uterine LMS
(see Supplementary Table S2–S3 online). There were 7 of 19 tumors
without detectable mutations in the JAK1, JAK2 or LMP2 promoter
regioninourtestedsamples,whichimpliedthatfurtherexperiments
might uncover additional somatic mutations in the catalytic subunit
(p110) of PI3K or PKC-d. MOTIF Search profiling
28 and NCBI’s
Conserved Domain Database and Search Service, v2.17 analysis
29,
revealed that the somatic mutations identified in the catalytic
domains of these genes resulted in impaired activation of tyrosine
kinases or transcriptional factors.
In a recent report, a comparative genomic hybridization (CGH)-
based analysis of LMS patients using a high resolution genome-wide
array gave gene-level information about the amplified and deleted
regions that may play a role in the development and progression of
human uterine LMS. Other reports showed that among the most
intriguing changes in genes were losses of JAK1 (1p31-p32) and
LMP2 (6p21.3)
30–32. It has also been demonstrated that a correlation
exists between the development of malignant tumors and ethnic
background, so we conducted CGH experiments with tissue samples
obtained from Japanese patients in order to obtain gene-level
information. Our results showed that LMS having a clear functional
loss at JAK1 (1p31-p32) and LMP2 (6p21.3) also harbored one non-
sense mutation and one deletion, suggesting a possible homozygous
loss of function (see Supplementary Fig. S8 online). The discovery of
these mutational defects in a key cell-signaling pathway may be
importantinunderstandingthepathogenesisofhumanuterineLMS.
Defective LMP2 expression due to somatic mutations in catalytic
domains of JAK1. It appeared likely that IFN-c-inducible LMP2
Figure 2 | Key role of the IFN-c-pathway in LMP2 expression in normal myometrium. (a) Key role of the signaling pathway on LMP2 expression.
(b)Immunohistochemical experimentswithmyometriumtissuesectionsderivedfromwild-type,IFN-c-deficient,andTNF-a-deficientmice(2months
old) were carried out. (magnification x100) The results revealed that the IFN-c signaling cascade was required for basal LMP2 expression. (c) Western
blotting and RT-PCR experiments with myometrium tissue sections derived from wild-type and IFN-c- and TNF-a-deficient mice (2 months old) were
also performed. The results showed that IFN-c-deficient mice had markedly reduced LMP2 levels in myometrium tissues. These findings support the
notion that the IFN-c pathway plays a key role in basal LMP2 expression. (d) Schematic representation of the LMP2/TAP1 bidirectional promoter,
including NF-kB and IRF-1 binding sites. Chromatin immunoprecipitation (ChIP) analysis with antibodies against RelA (NF-kBp65) and IRF-1 was
carried out. (e) ChIP assays showing that although mouse genomic DNA of the Lmp2 enhancer/promoter region was markedly amplified using
immunoprecipitated TNF-a-deficient myometrium tissue with anti-IRF-1 antibody, amplified products were not detected using immunoprecipitated
IFN-c-deficientmyometriumtissuewithanti-IRF-1antibody.ThemousegenomicDNAoftheLMP2enhancer/promoterregionwasunclearlyamplified
using the immunoprecipitated materials with anti-RelA antibody. Positive control (P.C.): IFN-c-treated mouse embryonic fibroblasts (lane 6), TNF-a-
treatedmouse splenocytes (lane11). (f)ChIP assays showingthat although human genomicDNA ofthe LMP2enhancer/promoter region wasmarkedly
amplifiedusingimmunoprecipitated LMAtissueaswellasnormalmyometrium tissuewithanti-IRF-1antibody, no-DNAamplificationwasdetectedin
the immunoprecipitated LMS sample with anti-IRF-1 antibody. The DNA of the LMP2 enhancer/promoter region was not clearly amplified using any
immunoprecipitatedmyometriumtissuematerialswithanti-RelAantibody.Positivecontrol(P.C.):IFN-c-treatedmouseembryonicfibroblasts(lane6),
TNF-a-treated mouse splenocytes (lane 11). N.IgG, normal rabbit anti-serum was usedasa negativecontrol antibody. The experiments were performed
four times with similar results.
www.nature.com/scientificreports
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domains, ATP-binding region, or kinase active site of JAK1 of the
IFN-c-pathway in uterine LMS. To evaluate whether a mutation
resulted in the loss of a transcriptional response to IFN-c, wild-
type JAK1 (JAK1wt) or JAK1 mutant expression vectors were
transiently introduced into JAK1-null cells. Western blotting and
RT-PCR analyses showed that although exogenous JAK1wt
restored the IFN-c inducibility of LMP2 expression, phospho-
JAK1(p-JAK1) and phospho-STAT1(p-STAT1) could not be
induced by any exogenous JAK1 mutant except JAK1-G986P
(Fig. 3). Similarly, electrophoresis mobility shift assays (EMSA)
demonstrated that the DNA-binding activity of STAT1 and IRF-1
tospecificregionswasabsentinthepresenceofanyexogenousJAK1
mutant except JAK1-G986P but was rescued by inclusion of JAK1wt
(Fig. 3).
Immunoblotting revealed that IFN-cR1, a component of the IFN-
c receptor, was expressed in LMS tissue sections at levels similar to
thoseinnormaltissuesectionsfrompatients(seeSupplementaryFig.
S9online). SincetheuterineLMStissue sectionshadlevels ofsurface
IFN-cR1 chains comparable to those in normal tissue sections
derivedfrompatientuterineorgans,thelossofIFN-cresponsiveness
could not be attributable to inadequate surface expression of this
component. IHC experiments with antibodies against JAK1 and
STAT1 showed strongly positive cells in uterine LMS tissue sections
and myometrium (see Supplementary Fig. S10 online). In contrast,
although p-STAT1 was weakly positive in normal myometrium tis-
suesections,itwasessentiallynegativeinuterineLMStissuesections
from the same patients (see Supplementary Fig. S10 online).
Therefore,thelossofIFN-cresponsivenessinuterineLMSmayhave
been due to the inadequate kinase activity of JAK1 stemming from
mutations in its catalytic domains.
Biological significance of hLMP2 in uterine leiomyosarcoma
tumorigenesis. Although cell proliferation has been demonstrated
to be strongly inhibited by IFN-c-induced JAK1 kinase activation
33,
it is difficult to demonstrate tumorigenicity in JAK1-deficient
mice because they die perinatally
34. Therefore, the differential
responsiveness to genetically modified stable LMP2 expression of
the SKN human uterine LMS cell line was investigated to
determine whether reintroducing LMP2 to a LMS cell line would
affect its tumorigenic properties for development of uterine LMS
and if the observed effect was due to the immunoproteosomal
function of the protein. SKN cells (approximately 53l0
5 cells) were
transfected with 5 mg of control vector DNA (pCEM9), pCEM9-
LMP2wt, or pCEMp-LMP2K33A, which has no effect on immu-
noproteasome function due to non-incorporation into the 20 S
proteasome (see Supplementary Fig. S11 online), and selected in
medium containing 1 mg/ml of G418. The efficiencies of neo-
marker transfer with these three plasmids were comparable (see
Supplementary Table S4 online). However, in the case of pCEM9-
LMP2wt or pCEM-LMP2K33A, approximately 78% (LMP2wt) or
76%(LMP2K33A)ofthetotalG418-resistantcolonieswererelatively
compact and appeared dark when observed under a phase-contrast
microscope after 6–7 days of selection. These partially flat (P/F type)
colonies consisted of cells with increased attachment to the sub-
strate, while the majority of other transformed (T type) colonies
looked similar in cell morphology to the cells observed in the
control dishes, albeit slightly smaller in size (Fig. 4a and see
Figure 3 | Somatic JAK1 mutations prevent LMP2 expression. (a) JAK1 mutants resulted in defective activation of downstream IFN-c pathways, as
described in Table S3. Activation of JAK1, STAT1, and IRF-1 for LMP2 expression by IFN-c in cells expressing JAK1WT and JAK1 mutants. Protein
lysates ofJAK1-deficient cells expressingwild-type andJAK1 mutants wereanalyzed by Western blotting (W.B.) usingappropriate antibodies. JAK1and
STAT1 phosphorylation after 15 minutes of stimulation was consistently increased in cells expressing JAK1WT and JAK1G986P, but phosphorylated
proteins were not detected in cells expressing other JAK1 mutants. IRF-1 and LMP2 expression was markedly activated in cells expressing JAK1WT and
JAK1G986P. There was no difference in the expression of JAK1, STAT1, SP1, or b-Actin among cells expressing wild-type and JAK1 mutants.
(b) Defective DNA-binding activities of IRF-1 and STAT1 suggest that LMP2 expression is attributable to mutations in the catalytic domains of JAK1.
DNA-binding activities of SP1 were detected in all tested samples. RT-PCR supported W.B. results. The experiments were performed three times with
similar results. Direct sequencing demonstrated that the mutations detected in the catalytic sites were indeed somatic mutations (details in
Supplementary Fig. S7 online).
www.nature.com/scientificreports
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colonies outgrew and detached from the substrate, some colonies
consisting of flatrevertant (F type) cells were found (Fig. 4a and see
SupplementaryFig. S12–S13online)atfrequencies ofapproximately
29.5% (pCEM9-LMP2wt) or 24.8% (pCEM-LMP2K33A) of the
total number of G418-resistant colonies initially observed (see
Supplementary Table S4 online). No colonies of this flatrevertant
morphology were observed in the cultures transfected with control
DNA (Table 1 and see Supplementary Table S4 online).
We next isolated and expanded representative colonies of each
type and analyzed their growth properties and the occurrence and
expression of LMP2. The growth rate, expressed as doubling time,
of typical SKN-LMP2wt (F type) colonies (8 clones) or SKN-
LMP2K33A (F type) colonies (4 clones) was generally lower than
that of SKN-LMP2wt (P/F type) colonies (2 clones) and control
SKN-CEM9 (T type) colonies (4 clones) (Fig. 4c, Table 1 and see
Supplementary Table S5 online). FACS analysis demonstrated that
LMP2 expression might have induced G1 arrest in the cell cycle of
SKN-LMP2 (F type) colonies (see Supplementary Fig. S14 online).
In trials evaluating the anti-tumorigenic properties of LMP2wt or
LMP2K33A, the efficiency of colony formation and size of the col-
onies in soft agar were greatly reduced in the F type clones and P/F
type clones and were significantly reduced in the morphologically
similar T type SKN-LMP2wt or SKN-LMP2K33A transfectant
clones compared with those in the SKN-CEM9 (T type) clone
(Fig. 4b,c, Table 1 and see Supplementary Table S5 online). Tumor
growth was clearly observed in control mice inoculated with the
SKN-CEM9 (T type) clones; however, a reduction in tumor growth
was observed in mice inoculated with the SKN-LMP2wt (F type)
clone or SKN-LMP2K33A (F type) clone (Fig. 4d, Table 1 and see
Supplementary Fig. S15 online). Since both wild type and mutant
LMP2 blocked tumorigenesis, it became necessary to rule out a
toxic effect of LMP2 overexpression in a control cancer cell line.
Additional experiments demonstrated no toxic effect of either wild
type LMP2 or mutant LMP2K33A overexpression in a HeLa control
cancer cell line (see Supplementary Fig. S16 and Supplementary
Table S6–S7 online). It is noteworthy that although calponin h1
may function as a tumor suppressor in uterine LMS, calponin h1-
deficient mice do not exhibit uterine LMS
35,36. To examine the con-
nection between LMP2 and calponin h1 in tumorigenesis, we ana-
lyzed the expression pattern of calponin h1 in SKN-CEM9 (T type)
clones and SKN-LMP2wt (F type) clones. Our results revealed that
calponin h1 expression was dependent on the presence of LMP2,
suggesting that the anti-oncogenic function of calponin h1 may be
involved with that of LMP2 in human uterine LMS (Table 1 and see
Supplementary Table S5 online).
The dysregulation of apoptotic mechanisms has also been assoc-
iated with many human malignancies. Whereas the mechanical link
of the NF-kB family with LMP2 for anti-apoptotic functions has
been reported, other lines of evidence suggest that NF-kB activity
is modulated by tumor suppressors, including TP53 and ARF,
wherebyNF-kBsubunitsrepress,ratherthanactivate,theexpression
of tumor-promoting genes
37–42. The nuclear NF-kB activation in
LMS tissue samples was reduced as in SKN-CEM9 (T-type) clones
in comparison with myometrium and LMA tissue samples, and thus
they were susceptible to TNF-a-induced apoptosis due to defective
NF-kB expression. Tumors grew more slowly in mice inoculated
with the SKN-p50p65 (T type) clones, which had exogeous NF-kB
Figure 4 | Biological activity of hLMP2 in uterine leiomyosarcoma (LMS). (a) Phase-contrast micrographs of the parental transformed SKN-CEM9 (T
type) clone and flat revertants of the SKN-LMP2 (F type) clone. (magnification x100) (b) Phase-contrast micrographs of the colony formations of the
SKN-CEM9 (T type) clone and SKN-LMP2 (F type) clone in soft agar. (magnification x40) (c) The table indicates the biological properties of the
transfectants, whose details are described in Table 1 and Supplementary Table 5. (d) Changes in the human uterine LMS cell line, SKN transfectants, the
SKN-CEM9 (T type) clone, and the SKN-LMP2 (F type) clone xenograft volumes in mice (n58). Representative photographs of xenografts in mice
(Upper panel). Tumor growth of SKN-LMP2 was markedly reduced in comparison with that of the control transfectant SKN-CEM9 (T type) clone.
Tumor growth kinetics after subcutaneous injection of the SKN-CEM9 (T type) clone and SKN-LMP2 (F type) clone (Lower panel). RT-PCR
experiments reveal hLMP2 mRNA expression in tumors (Lower right panel). The experiments were performed four times with similar results.
www.nature.com/scientificreports
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Supplementary Table S5 online). These findings suggested that
NF-kB activation was not involved in the tumorigenesis of human
uterine LMS, and strengthened the overall notion that the suppres-
sion of cell proliferation, tumorigenesis, and morphological change
of uterine LMS cells observed under stable LMP2 expression was
attributable tothebiologicalfunction of single-molecule LMP2only,
without involvement of its immunoproteasome function.
Discussion
Recent molecular targeting therapies against tumors have achieved
remarkableresults.ToimprovetheprognosisofhumanuterineLMS,
studiesarebeingperformedtoidentifytherolesofkeypro-andanti-
oncogenicfactors that have important functionsin tumor pathogen-
esis and may serve as molecular targets for treatment. For this pur-
pose, several research groups have shown that cell cycle regulatory
factors and known pro-oncogenic factors, such as the brain-specific
polypeptide PEP-19 and c-kit, may be associated with the pathogen-
esis of human uterine LMS
43–46.
LMP2-deficient mice are reportedly prone to spontaneous
development of uterine LMS
14. The percentage of mice with overt
tumorsincreasedwithageaftersixmonths,withacumulativedisease
prevalence of40% infemalemice by14monthsof ageand noappar-
ent plateau at this late observation time. In the present study, histo-
pathologicalexperimentsdemonstrated ahighcorrelationbetweena
loss of LMP2 and malignancy of uterine tumors developing in myo-
metrium. Thus, LMP2 may constitute a diagnostic biomarker that is
able to distinguish between LMS and LMA. Recent reports have also
shown a loss in the IFN-c-inducible expression of LMP2 in a LMS
culture cell line
13. It is intriguing that only LMP2-deficient mice
spontaneously develop uterine LMS, and the individual expression
of LMP2, LMP7, and LMP10/MECL-1 subunits have been reported
to contribute to the initiation and development of disorders
12,14,15.
Our histopathological examinations with IFN-c-deficient and TNF-
a-deficient mice revealed that the IFN-c pathway is especially
required for LMP2 expression in normal myometrium. Therefore,
organ-specific LMP2 functions might be one of the factors influ-
encing disease development in mice and humans.
The functionally inactivated K33A mutant of LMP2 has the
same morphology in vitro as the wt transfectant, suggesting that
the action of LMP2 is not only through its role in immunoprotea-
somes, but also as a single subunit. The relative amounts of LMP2
and LMP7 messaging vary significantly among tissues of mice and
humans, as well as among different cell lines
47. Given the fact that
LMP2 levels in proteasomes showed greater variation among tis-
sues than did LMP7 levels, it may be possible that the constitutive
levels of both proteins can also differ in the proteasomes of mouse
and human tissues
47. The proteasome subunits that are not incor-
porated into complexes are believed to individually mediate gene
transcriptional activation together with other co-factors
48;f o r
instance, LMP2 is also reportedly required for estrogen recep-
tor-mediated gene transcription as well as for estrogen-stimulated
cell cycle progression
49. Other reports have demonstrated the nuc-
lear localization of single-unit LMP2 in various mammalian tis-
sues and cell types
47,50, but the biological functions of LMP2 in the
nucleus are not clearly understood. Our additional results have
revealed an interaction between LMP2wt or LMP2K33A with
RNA polymerase II holoenzymes that is capable of responding
to a transcriptional activator or co-factor, suggesting a model in
which activators function, in part, through direct interactions with
the holoenzyme. Unfortunately, no evidence of LMP7 association
with holoenzyme components was observed. Further experiments
may provide a more complete description of the tumorigenic
phenotype of SKN cells by nonproteosomal LMP2.
Table 1 | Biological Properties of the Transfectants.
Cell line Molphology PDT
a
SoftAgarColony
Efficiency(%)
bSize
c
Tumori-
genecity
d
Protein Expression
e
Inco
LMP2
f
iTNF-a
Cell death LMP2 LMP7 Calponin Fibronectin
SKN
hTransformed 15.0 53 11–29 111 W L - L - Sen.
SKN-CEM9#1 Transformed 15.2 67 10–26 111 W L - L - Sen.
SKN-CEM9#2 Transformed 15.2 63 11–28 11 W L - L - Sen.
LMP2wt#230 P.Flat. 15.4 6.2 5–9 1 ML L M 1 Resi.
LMP2wt#231 P.Flat. 16.8 6.4 6–10 1 ML L M 1 Resi.
LMP2wt#196 Flatrevertant 17.3 5.4 4–9 1 HH M H 1 Resi.
LMP2wt#198 Flatrevertant 17.4 5.6 5–10 1 HH H H 1 Resi.
LMP2wt#120 Flatrevertant 17.5 4.9 4–11 1/- H H M H 1 Resi.
LMP2wt#121 Flatrevertant 17.3 4.7 5–9 1/- H M M H 1 Resi.
LMP2wt#122 Flatrevertant 17.6 5.4 4–12 1 HM M M 1 Resi.
LMP2wt#124 Flatrevertant 17.5 5.9 6–10 1 HM M H 1 Resi.
LMP2wt#125 Flatrevertant 17.8 5.8 5–12 1/- H M M H 1 Resi.
LMP2wt#127 Flatrevertant 17.3 4.5 5–10 1 HM M H 1 Resi.
LMP2K33A#1 Flatrevertant 17.5 6.2 5–13 1 H M M H - Sen.
LMP2K33A#2 Flatrevertant 16.8 6.1 6–11 1/- H M M H - Sen.
LMP2K33A#3 Flatrevertant 17.3 5.9 5–10 1/- H M M H - Sen.
LMP2K33A#4 Flatrevertant 17.2 6.4 6–8 1 H M M H - Sen.
CryoUTSMC
g Flatrevertant 19.4 ,0.5 - - M M H H - Resi.
aPDT: Population Doubling Time.
bRatio(%) of soft agar colonies/number of cells plated that have an ability to form colonies on plastic substrate.
cDiameter of colonies as expressed by the number of cells lined up across the colonies; determined on day 21. The experiments were repeated three times with similar results.
dCells(1x10
7) wereinoculated subcutaneouslyinto 7–8-weeksold nude mice,and the mice were periodically examinedfor evidenceof tumors,-, noevidence of tumors;1/-, tumorsof ,0.5 cmdiameter;
1, tumors of 0.5–1.0 cm diameter; 11, tumors of 1.0–1.5 cm diameter, 111, tumors of 1.5–2.0 cm diameter, in two inoculated mice. Experiments were terminated at 5 weeks after inoculation.
eEstimated by immunoblot analysis. W, weak expression; L, low expression; M, medium expression; H, high expression; -, no evidence of expression.
fIncorporationof LMP2intoproteasomecomplexes.Proteasomewasisolated byGST-UbLbeadsinaccordancewithmanufacturer’srecomendation(MerckLtd.Darmstadt,Germany).Immunoblotanalysis
was performed. -, no evidence of expression; 1, Detectable expression of LMP2 by immunoblot analysis.
gCryo UtSMC: normal human uterine liomyosarcoma cell line (Cambrex BioScience Walkersville, Inc. MD, USA).
hMorphology.After2to3weeks,whenmostofthecoloniesoutgrewanddetachedfromthesubstrate,somecoloniesconsistingofveryflatcellswerefoundatfrequenciesofaroundafewpercentofthetotal
number of G418-resistant colonies initially observed in Table S4. Microscopic characteristics such as flat cell morphology and transformed cell morphology were analyzed. The number of flat cells or
transformed cells in 10 consecutive high-power-fields was counted. Transformed, no evidence about appearance of flat cells; Flatrevertant, transformed cell number is less than 10% of total cell number;
P.Flat., Partially Flatrevertant, transformed cell number is less than 30% of total cell number; P.Tras., Partially Transformed, transformed cell number is higher than 30% of total cell number.
iTNF-a induced cell death. Sen., Sensitive to TNF-a-induced cell death; Resi., Resistant to TNF-a-induced cell death.
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in tumorigenesis, but only a few serine/threonine kinases are known
to be mutated in human cancers
51–53. For example, mice carrying a
homozygous deletion of Pten alleles developed widespread smooth
muscle cell hyperplasias and abdominal sarcomas, and JUN onco-
geneamplificationandoverexpressionblockedadipocyticdifferenti-
ation in highly aggressive sarcomas
54–57. The molecular basis for
genetic alterations remains unclear, and therefore we performed
geneticstudiestoexploresuchagenotype-tumorigenesiscorrelation.
Our findings demonstrated that the IFN-c signaling pathway played
a key role in LMP2 expression in myometrium. Intriguingly, we
observed a significantly higher representation of somatic mutations
in the catalytic domain of JAK1 in uterine LMS compared with
patient-matched myometrium. Although heterozygosity for somatic
mutations was demonstrated to be significantly more frequent in
uterine LMS, the evaluation of a genotype-tumorigenesis correlation
might not be statistically significant between heterozygotes and
homozygotes due to our small sample size. In addition, genetic
alteration in other malignant tumors reportedly occur in genes of
the MAPK signaling, p53 signaling, Wnt signaling, cell cycle, and
mTOR pathways
51–57. Thus, genetic analyses of other signaling path-
ways are also needed to explore the genotype-tumorigenesis correla-
tion for this disease. From our data, we can infer a heterogeneous
genetic background of JAK somatic mutations, but we cannot defi-
nitively conclude tumorigenesis by genotype.
Proteasome subunits are assembled in the cytoplasm, and most
subunits, including LMP2, do not contain a nuclear localization
signal. It is thus unclear how proteasomes enter the nucleus
55,56.
LMP2moleculesreportedlyassociatewithcellularfactor(s)andthen
regulate cellular processes, including cell cycle and the regulation of
gene expression. Recent studies indicate that a tuned balance of
proteolysis by LMP2-incorporating proteasomes and cellular
function(s) by LMP2-associated complexes with cellular factor(s) is
instrumental for normal cellular processes and, when deregulated,
leads to the development of disease. The downregulation of MHC-
related molecules, including LMP2, is one of the biological mechan-
isms used by tumor cells to evade host immunosurveillance
58.
Furthermore, LMP2 expression appears to suppress cell transforma-
tion, proliferation, and tumorigenesis in uterine LMS cells, which
suggests that LMP2 plays a key role as a tumor suppressor in uterine
LMS.
Defective LMP2 expression is likely to be one of the risk factors in
thedevelopmentofhumanuterineLMSasitisintheLMP2-deficient
mouse. Overall, nearly 96% (52/54) of our uterine LMS patients had
alterations in LMP2 expression, and thus this protein represents
a strong candidate target for therapeutic intervention. As there
remains no effective therapy for unresectable uterine LMS, our
results may lead to the development of diagnostic approaches and
specific molecular therapies to treat this disease.
Methods
Immunohistochemistry (IHC). IHC staining for LMP2, ER, PR, p53, and Ki-67 was
performed on serial human uterine LMS sections. Antibodies for ER (ER1D5), PR
(PR10A), p53 (DO-1), and Ki-67(MIB-1) were purchased from Immunotech
(Marseille, France).The antibodies for Stat1, p-Stat1, and NF-kBp50 were purchased
fromSantaCruzBiotechnologyInc.(CA,USA).TheantibodyforJak1waspurchased
from Chemicon International (CA, USA). The antibody for NF-kBp65(RelA) was
purchased from Applied Biological Materials, Inc. (BC, Canada). The antibody for
fibronectin was purchased from Rockland Inc. (PA, USA). The antibody for a-
Smooth muscle actin (SMA) was purchased from Covance Research Products, Inc.
(Princeton,NewJersey).TheLMP2antibodywasproducedbySIGMA-AldrichIsrael
Ltd. (Rehovot, Israel) (see Supplementary Fig. 2 online). IHC was performed using
the avidin-biotin complex method as described previously
15,39. Briefly, one
representative 5-mm tissue section was cut from a paraffin-embedded sample of a
radical hysterectomy specimen from each patient with uterine LMS. Uterine tissue
sections from adult C57BL/6J, IFN-c
2/2, and TNF-a
2/2 mice on C57BL/6J genetic
backgrounds (10 weeks old), which were donated by Dr. Y. Tagawa (Tokyo Inst. of
Tech., Yokohama, Japan, details in Supplemental Material), were fixed with 1%
buffered formalin, and paraffin sections ofmouse uterine tissues wereanalyzed using
IHC staining with and without either antibody to LMP2 or normal rabbit IgG as a
negative control. Sections obtained from patients or gene-deficient mice were
deparaffinized and rehydrated in graded concentrations of alcohol, incubated with
normal mouse serum for 20 min, and then incubated at room temperature for 1 h
with primary antibody. Afterwards, sections were incubated with a biotinylated
secondary antibody (Dako, CA, USA) and then exposed to a streptavidin complex
(Dako). The completed reaction was revealed by 3, 39-diaminobenzidine, and the
slide was counterstained with hematoxylin. Normal myometrium portions in the
specimens were used as positive controls. Negative controls consisted of tissue
sections incubated with normal rabbit IgG instead of the primary antibody. These
experimentswereregisteredatShinshuUniversityinaccordancewithlocalguidelines
(approval no. M192).
Reverse Transcription-polymerase Chain Reaction Analysis (RT-PCR). The
expressionofLMP2andb-actintranscriptswasexaminedusingRT-PCR.TotalRNA
was prepared from human uterine LMS tissues and normal myometrium tissues
using TRIzol reagent according to the manufacturer’s protocol (Invitrogen Co., CA,
USA). The RNA was reverse-transcribed with the Superscript II enzyme (Invitrogen
Co.), and single stranded cDNA was used for amplification. LMP2 and b-actin
transcripts were subjected to PCR with the appropriate primer sets following a
program of 35 cycles at 94uC for 30 s, 60uC for 30 s, and 72uC for 1.5 min with
an additional 5 min for the extension of transcripts
15. The primers were used as
follows: LMP2 (F 59-gggatagaactggagg aacc-39,R5 9-agatgacacccccgcttgag-39), LMP7
(F 59-gaacacttatgcctacggggtc-39,R5 9-tttctactttcac ccaaccatc-39), Calponin h1
(F 59-ggaaggcagctgaggttgtg-39,R5 9-cccaagct cagggctctggcctggc-39), and b-Actin
(F 59-tccggagacggggtca-39,R5 9-cctgcttgctgatcca-39). These experiments were
conducted at Shinshu University in accordance with local guidelines (approval
no. 4737, no. 150, and no. M192).
Chromatin Immunoprecipitation (ChIP) Analysis. Cells prepared from tissues
were washed in PBS with protease inhibitors and centrifuged. The cells were
resuspended in 1% SDS,10 mMEDTA, and 50 mMTris-HCl, pH 8.0,with protease
inhibitors and sonicated. Samples were diluted (1/10 in 0.01% SDS, 1.1% Triton-
X100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.0, and protease
inhibitor),preclearedwithproteinGbeadsandsalmonspermDNA,andcentrifuged.
The supernatants were incubated with primary antibody against the protein of
interest between 4 h and overnight at 4uC. Antisera were anti-RelA (Upstate, MA),
anti-IRF-1(SantaCruz,CA,USA),anti-SP1(SantaCruz)ornormalrabbitIgG(Santa
Cruz). After multiple washes, samples were eluted and cross-links reversed with 5 ml
of 5 M NaCl. Samples were purified before PCR amplification. Primer sequences
were as follows: human LMP2 (F 59-cgagaagctcagccatttaggggaaag cga-39,R5 9-
cgcccgcagcatccctgcaaggcaccgctc-39) and mouse Lmp2 (F 59-tgcgcagccatcgagcgtga
gctgtccaga-39,R5 9-gcccgcagcatctca gcagagcggggctcg-39).
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